Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Ateganosine

Source date not recordedAnalyse record ↗

Direct telomere-targeting anticancer nucleoside in recruiting Phase 3 development for advanced non-small-cell lung cancer.

Modality
telomerase-recognized modified nucleoside that induces telomeric DNA damage in cancer cells
Availability (US)
Phase 3 THIO-104 study Recruiting; Phase 2 THIO-101 Active, not recruiting
Biomarkers
overall survival; dose-limiting toxicities; treatment-emergent adverse events; objective response; disease control; telomere-associated DNA damage
Hallmark targeted
telomere biology, genomic instability, cancer-cell immortality
Kind
investigational drug
Clinical trials
NCT06908304 — Phase 3, Recruiting on January 12, 2026 update; NCT05208944 — Phase 2, Active, not recruiting on September 16, 2026 update